新辅助免疫治疗在可切除非小细胞肺癌中的应用前景  

Progress in neoadjuvant immunotherapy for resectable non-small cell lung cancer

作　　者：谭晓刚[1] 张毅[1] Tan Xiaogang;Zhang Yi(Department of Thoracic Surgery,Xuanwu Hospital,Capital Medical University,Beijing 100053,China)

机构地区：[1]首都医科大学宣武医院胸外科,北京100053

出　　处：《首都医科大学学报》2021年第5期862-867,共6页Journal of Capital Medical University

摘　　要：可切除非小细胞肺癌作为一种潜在的可治愈性疾病,接受根治性手术或辅以化学药物治疗及放射治疗(以下简称放化疗)仍是目前标准的治疗方法,但仍有部分患者术后出现局部复发和远处转移。近期研究结果显示,将免疫治疗用于新辅助治疗的初步结果令人振奋,可使20%~85%的病例获得主要病理学缓解,优于既往新辅助化疗,提示免疫检查点抑制剂在可切除非小细胞肺癌新辅助治疗应用中非常具有潜力。本文针对免疫治疗对可切除非小细胞肺癌患者的疗效、治疗中的潜在风险予以综述。随着免疫检查点抑制剂进入国家医保,新辅助免疫治疗必将为可切除非小细胞肺癌患者带来崭新的治疗模式和希望。Resectable non-small cell lung cancer(NSCLC)is known as a potentially curable disease.Radical surgery or adjuvant chemotherapy and radiotherapy is the standard treatment,but quite a few patients will have local recurrence and distant metastasis after surgery.More recent publications indicate that immune checkpoint blockade may have better potential in neoadjuvant therapy,with reported major pathological response rates of 20%to 85%,compared to chemotherapy alone.This review intends to summarize the efficacies and potential risks of neoadjuvant targeted therapy and immunotherapy in patients with NSCLC.With more and more independent research and development of immune checkpoint inhibitors listed in China,we discussed the future developments in neoadjuvant therapy.

关 键 词：非小细胞肺癌 可切除 免疫检查点抑制剂 新辅助治疗 

分 类 号：R734.2[医药卫生—肿瘤]